

Angelika Eggert

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8845270/publications.pdf>

Version: 2024-02-01

235
papers

13,024
citations

22099

59
h-index

30010

103
g-index

261
all docs

261
docs citations

261
times ranked

16742
citing authors

#	ARTICLE	IF	CITATIONS
1	The landscape of genomic alterations across childhood cancers. <i>Nature</i> , 2018, 555, 321-327.	13.7	1,068
2	Telomerase activation by genomic rearrangements in high-risk neuroblastoma. <i>Nature</i> , 2015, 526, 700-704.	13.7	478
3	Lysine-Specific Demethylase 1 Is Strongly Expressed in Poorly Differentiated Neuroblastoma: Implications for Therapy. <i>Cancer Research</i> , 2009, 69, 2065-2071.	0.4	405
4	Neuroblastoma: Biology, Prognosis, and Treatment. <i>Hematology/Oncology Clinics of North America</i> , 2010, 24, 65-86.	0.9	388
5	LIN28B induces neuroblastoma and enhances MYCN levels via let-7 suppression. <i>Nature Genetics</i> , 2012, 44, 1199-1206.	9.4	336
6	Overall Genomic Pattern Is a Predictor of Outcome in Neuroblastoma. <i>Journal of Clinical Oncology</i> , 2009, 27, 1026-1033.	0.8	288
7	Next-generation personalised medicine for high-risk paediatric cancer patients – The INFORM pilot study. <i>European Journal of Cancer</i> , 2016, 65, 91-101.	1.3	262
8	Mutational dynamics between primary and relapse neuroblastomas. <i>Nature Genetics</i> , 2015, 47, 872-877.	9.4	253
9	MYCN regulates oncogenic MicroRNAs in neuroblastoma. <i>International Journal of Cancer</i> , 2008, 122, 699-704.	2.3	251
10	Neuroblastoma: Biology, Prognosis, and Treatment. <i>Pediatric Clinics of North America</i> , 2008, 55, 97-120.	0.9	247
11	Meta-analysis of Neuroblastomas Reveals a Skewed <i>ALK</i> Mutation Spectrum in Tumors with <i>MYCN</i> Amplification. <i>Clinical Cancer Research</i> , 2010, 16, 4353-4362.	3.2	243
12	A mechanistic classification of clinical phenotypes in neuroblastoma. <i>Science</i> , 2018, 362, 1165-1170.	6.0	213
13	Loss of caspase-8 mRNA expression is common in childhood primitive neuroectodermal brain tumour/medulloblastoma. <i>European Journal of Cancer</i> , 2002, 38, 83-91.	1.3	212
14	Childhood cancer predisposition syndromes – A concise review and recommendations by the Cancer Predisposition Working Group of the Society for Pediatric Oncology and Hematology. <i>American Journal of Medical Genetics, Part A</i> , 2017, 173, 1017-1037.	0.7	200
15	Extrachromosomal circular DNA drives oncogenic genome remodeling in neuroblastoma. <i>Nature Genetics</i> , 2020, 52, 29-34.	9.4	193
16	Deep sequencing reveals differential expression of microRNAs in favorable versus unfavorable neuroblastoma. <i>Nucleic Acids Research</i> , 2010, 38, 5919-5928.	6.5	183
17	Resistance to chemotherapy mediated by TrkB in neuroblastomas. <i>Cancer Research</i> , 2002, 62, 6462-6.	0.4	182
18	Lysine-specific demethylase 1 restricts hematopoietic progenitor proliferation and is essential for terminal differentiation. <i>Leukemia</i> , 2012, 26, 2039-2051.	3.3	171

#	ARTICLE	IF	CITATIONS
19	Resistance to TRAIL-induced apoptosis in primitive neuroectodermal brain tumor cells correlates with a loss of caspase-8 expression. <i>Oncogene</i> , 2000, 19, 4604-4610.	2.6	169
20	Targeted Expression of Mutated ALK Induces Neuroblastoma in Transgenic Mice. <i>Science Translational Medicine</i> , 2012, 4, 141ra91.	5.8	147
21	Targeting MYCN-Driven Transcription By BET-Bromodomain Inhibition. <i>Clinical Cancer Research</i> , 2016, 22, 2470-2481.	3.2	147
22	Human fetal neuroblast and neuroblastoma transcriptome analysis confirms neuroblast origin and highlights neuroblastoma candidate genes. <i>Genome Biology</i> , 2006, 7, R84.	13.9	134
23	BET bromodomain protein inhibition is a therapeutic option for medulloblastoma. <i>Oncotarget</i> , 2013, 4, 2080-2095.	0.8	122
24	Prediction of clinical outcome and biological characterization of neuroblastoma by expression profiling. <i>Oncogene</i> , 2005, 24, 7902-7912.	2.6	113
25	The Phox2B homeobox gene is mutated in sporadic neuroblastomas. <i>Oncogene</i> , 2004, 23, 9280-9288.	2.6	112
26	MYCN/c-MYC-induced microRNAs repress coding gene networks associated with poor outcome in MYCN/c-MYC-activated tumors. <i>Oncogene</i> , 2010, 29, 1394-1404.	2.6	112
27	A Cre-conditional MYCN-driven neuroblastoma mouse model as an improved tool for preclinical studies. <i>Oncogene</i> , 2015, 34, 3357-3368.	2.6	112
28	Identification of a Set of Seven Genes for the Monitoring of Minimal Residual Disease in Pediatric Acute Myeloid Leukemia. <i>Clinical Cancer Research</i> , 2006, 12, 2434-2441.	3.2	111
29	The Pediatric Precision Oncology INFORM Registry: Clinical Outcome and Benefit for Patients with Very High-Evidence Targets. <i>Cancer Discovery</i> , 2021, 11, 2764-2779.	7.7	110
30	Gains and overexpression identify DEK and E2F3 as targets of chromosome 6p gains in retinoblastoma. <i>Oncogene</i> , 2005, 24, 6441-6449.	2.6	108
31	LifeTime and improving European healthcare through cell-based interceptive medicine. <i>Nature</i> , 2020, 587, 377-386.	13.7	108
32	High-Dose Chemotherapy and Blood Autologous Stem-Cell Rescue Compared With Standard Chemotherapy in Localized High-Risk Ewing Sarcoma: Results of Euro-E.W.I.N.G.99 and Ewing-2008. <i>Journal of Clinical Oncology</i> , 2018, 36, 3110-3119.	0.8	107
33	Biological effects of TrkA and TrkB receptor signaling in neuroblastoma. <i>Cancer Letters</i> , 2005, 228, 143-153.	3.2	106
34	Enhancer hijacking determines extrachromosomal circular MYCN amplicon architecture in neuroblastoma. <i>Nature Communications</i> , 2020, 11, 5823.	5.8	104
35	Expression of the Neurotrophin Receptor TrkB Is Associated With Unfavorable Outcome in Wilmsâ€™ Tumor. <i>Journal of Clinical Oncology</i> , 2001, 19, 689-696.	0.8	99
36	High <i>ALK</i> Receptor Tyrosine Kinase Expression Supersedes <i>ALK</i> Mutation as a Determining Factor of an Unfavorable Phenotype in Primary Neuroblastoma. <i>Clinical Cancer Research</i> , 2011, 17, 5082-5092.	3.2	95

#	ARTICLE	IF	CITATIONS
37	miRNA Expression Profiling Enables Risk Stratification in Archived and Fresh Neuroblastoma Tumor Samples. <i>Clinical Cancer Research</i> , 2011, 17, 7684-7692.	3.2	92
38	MiR-137 functions as a tumor suppressor in neuroblastoma by downregulating KDM1A. <i>International Journal of Cancer</i> , 2013, 133, 1064-1073.	2.3	91
39	Incidence of second cancers after radiotherapy and systemic chemotherapy in heritable retinoblastoma survivors: A report from the German reference center. <i>Pediatric Blood and Cancer</i> , 2017, 64, 71-80.	0.8	90
40	IL-2-driven Regulation of NK Cell Receptors With Regard to the Distribution of CD16+ and CD16 ^{hi} Subpopulations and In Vivo Influence After Haploidentical NK Cell Infusion. <i>Journal of Immunotherapy</i> , 2010, 33, 200-210.	1.2	89
41	Accurate prediction of neuroblastoma outcome based on miRNA expression profiles. <i>International Journal of Cancer</i> , 2010, 127, 2374-2385.	2.3	88
42	Microarray analysis of Ewing's sarcoma family of tumours reveals characteristic gene expression signatures associated with metastasis and resistance to chemotherapy. <i>European Journal of Cancer</i> , 2008, 44, 699-709.	1.3	87
43	Molecular dissection of TrkA signal transduction pathways mediating differentiation in human neuroblastoma cells. <i>Oncogene</i> , 2000, 19, 2043-2051.	2.6	86
44	Accurate Outcome Prediction in Neuroblastoma across Independent Data Sets Using a Multigene Signature. <i>Clinical Cancer Research</i> , 2010, 16, 1532-1541.	3.2	86
45	Front-line imatinib treatment in children and adolescents with chronic myeloid leukemia: results from a phase III trial. <i>Leukemia</i> , 2018, 32, 1657-1669.	3.3	86
46	MYCN and ALK1174L are sufficient to drive neuroblastoma development from neural crest progenitor cells. <i>Oncogene</i> , 2013, 32, 1059-1065.	2.6	84
47	Modulation of neuroblastoma disease pathogenesis by an extensive network of epigenetically regulated microRNAs. <i>Oncogene</i> , 2013, 32, 2927-2936.	2.6	84
48	Expression of the neurotrophin receptor TrkA down-regulates expression and function of angiogenic stimulators in SH-SY5Y neuroblastoma cells. <i>Cancer Research</i> , 2002, 62, 1802-8.	0.4	81
49	miR-542b exerts tumor suppressive functions in neuroblastoma by downregulating <i>urvivin</i> . <i>International Journal of Cancer</i> , 2015, 136, 1308-1320.	2.3	78
50	Microarray analysis reveals differential gene expression patterns and regulation of single target genes contributing to the opposing phenotype of TrkA- and TrkB-expressing neuroblastomas. <i>Oncogene</i> , 2005, 24, 165-177.	2.6	76
51	2017 GPOH Guidelines for Diagnosis and Treatment of Patients with Neuroblastic Tumors. <i>Klinische Padiatrie</i> , 2017, 229, 147-167.	0.2	76
52	Using droplet digital PCR to analyze <i>MYCN</i> and <i>ALK</i> copy number in plasma from patients with neuroblastoma. <i>Oncotarget</i> , 2017, 8, 85234-85251.	0.8	71
53	Chromosomal and MicroRNA Expression Patterns Reveal Biologically Distinct Subgroups of 11q ^{am} Neuroblastoma. <i>Clinical Cancer Research</i> , 2010, 16, 2971-2978.	3.2	70
54	Progress in treatment and risk stratification of neuroblastoma: Impact on future clinical and basic research. <i>Seminars in Cancer Biology</i> , 2011, 21, 217-228.	4.3	70

#	ARTICLE	IF	CITATIONS
55	ArrayCGH-based classification of neuroblastoma into genomic subgroups. <i>Genes Chromosomes and Cancer</i> , 2007, 46, 1098-1108.	1.5	67
56	Polo-Like Kinase 1 is a Therapeutic Target in High-Risk Neuroblastoma. <i>Clinical Cancer Research</i> , 2011, 17, 731-741.	3.2	67
57	Angiogenic profile of childhood primitive neuroectodermal brain tumours/medulloblastomas. <i>European Journal of Cancer</i> , 2001, 37, 2064-2072.	1.3	65
58	The neurotrophin receptor TrkB cooperates with c-Met in enhancing neuroblastoma invasiveness. <i>Carcinogenesis</i> , 2005, 26, 2105-2115.	1.3	65
59	Temporal proteomics of NGF-TrkA signaling identifies an inhibitory role for the E3 ligase Cbl-b in neuroblastoma cell differentiation. <i>Science Signaling</i> , 2015, 8, ra40.	1.6	64
60	Targeting the Phosphoinositide 3-Kinase Isoform p110 β Impairs Growth and Survival in Neuroblastoma Cells. <i>Clinical Cancer Research</i> , 2008, 14, 1172-1181.	3.2	63
61	Fractalkine (CX3CL1)-enriched Neuroblastoma Microenvironment Induces Eradication of Metastases Mediated by T Cells and Natural Killer Cells. <i>Cancer Research</i> , 2007, 67, 2331-2338.	0.4	62
62	Resistance to TRAIL-induced apoptosis in neuroblastoma cells correlates with a loss of caspase-8 expression. <i>Medical and Pediatric Oncology</i> , 2000, 35, 603-607.	1.0	61
63	Galectin-1 is a major effector of TrkB-mediated neuroblastoma aggressiveness. <i>Oncogene</i> , 2009, 28, 2015-2023.	2.6	61
64	Biological stability of RNA isolated from RNAi-treated brain tumor and neuroblastoma xenografts. , 2000, 34, 438-442.		59
65	The SIOPE strategic plan: A European cancer plan for children and adolescents. <i>Journal of Cancer Policy</i> , 2016, 8, 17-32.	0.6	57
66	Oncogenic activation of FOXR1 by 11q23 intrachromosomal deletion-fusions in neuroblastoma. <i>Oncogene</i> , 2012, 31, 1571-1581.	2.6	55
67	Genotyping circulating tumor DNA of pediatric Hodgkin lymphoma. <i>Leukemia</i> , 2020, 34, 151-166.	3.3	53
68	Brainstem biopsy in pediatric diffuse intrinsic pontine glioma in the era of precision medicine: the INFORM study experience. <i>European Journal of Cancer</i> , 2019, 114, 27-35.	1.3	51
69	Reactivating TP53 signaling by the novel MDM2 inhibitor DS-3032b as a therapeutic option for high-risk neuroblastoma. <i>Oncotarget</i> , 2018, 9, 2304-2319.	0.8	51
70	Combined inhibition of Aurora-A and ATR kinases results in regression of MYCN-amplified neuroblastoma. <i>Nature Cancer</i> , 2021, 2, 312-326.	5.7	50
71	Pharmacological activation of the p53 pathway by nutlin-3 exerts anti-tumoral effects in medulloblastomas. <i>Neuro-Oncology</i> , 2012, 14, 859-869.	0.6	48
72	Neuroblastoma cells depend on HDAC11 for mitotic cell cycle progression and survival. <i>Cell Death and Disease</i> , 2017, 8, e2635-e2635.	2.7	48

#	ARTICLE	IF	CITATIONS
73	Expression of the tumour suppressor gene CADM1 is associated with favourable outcome and inhibits cell survival in neuroblastoma. <i>Oncogene</i> , 2008, 27, 3329-3338.	2.6	47
74	GADD45A and CDKN1A are involved in apoptosis and cell cycle modulatory effects of viscumTT with further inactivation of the STAT3 pathway. <i>Scientific Reports</i> , 2018, 8, 5750.	1.6	47
75	From class waivers to precision medicine in paediatric oncology. <i>Lancet Oncology</i> , The, 2017, 18, e394-e404.	5.1	45
76	Vascular Endothelial Growth Factor Plasma Levels Are Significantly Elevated in Patients with Cerebral Arteriovenous Malformations. <i>Cerebrovascular Diseases</i> , 2006, 21, 154-158.	0.8	42
77	The mutagenic potential of non-homologous end joining in the absence of the NHEJ core factors Ku70/80, DNA-PKcs and XRCC4-LigIV. <i>Mutagenesis</i> , 2007, 22, 217-233.	1.0	42
78	Accelerating drug development for neuroblastoma: Summary of the Second Neuroblastoma Drug Development Strategy forum from Innovative Therapies for Children with Cancer and International Society of Paediatric Oncology Europe Neuroblastoma. <i>European Journal of Cancer</i> , 2020, 136, 52-68.	1.3	42
79	Meta-mining of Neuroblastoma and Neuroblast Gene Expression Profiles Reveals Candidate Therapeutic Compounds. <i>Clinical Cancer Research</i> , 2009, 15, 3690-3696.	3.2	41
80	Smac Mimetic LBW242 Sensitizes XIAP-Overexpressing Neuroblastoma Cells for TNF- α -Independent Apoptosis. <i>Cancer Research</i> , 2012, 72, 2645-2656.	0.4	41
81	<i>M</i> <i>R</i> 34a deficiency accelerates medulloblastoma formation <i>in vivo</i> . <i>International Journal of Cancer</i> , 2015, 136, 2293-2303.	2.3	40
82	A Natural Combination Extract of <i>Viscum album</i> L. Containing Both Triterpene Acids and Lectins Is Highly Effective against AML <i>In Vivo</i> . <i>PLoS ONE</i> , 2015, 10, e0133892.	1.1	40
83	Neuroblastoma. <i>Critical Reviews in Oncogenesis</i> , 2015, 20, 245-270.	0.2	40
84	CD171- and GD2-specific CAR-T cells potently target retinoblastoma cells in preclinical <i>in vitro</i> testing. <i>BMC Cancer</i> , 2019, 19, 895.	1.1	40
85	Regulatory <i>BCL2</i> promoter polymorphism ($\hat{9}38C \rightarrow A$) is associated with adverse outcome in patients with prostate carcinoma. <i>International Journal of Cancer</i> , 2011, 129, 2390-2399.	2.3	39
86	How Eye-Preserving Therapy Affects Long-Term Overall Survival in Heritable Retinoblastoma Survivors. <i>Journal of Clinical Oncology</i> , 2016, 34, 3183-3188.	0.8	39
87	Haploidentical CD3 or $\hat{1}^2$ T-cell depleted HSCT in advanced stage sickle cell disease. <i>Bone Marrow Transplantation</i> , 2019, 54, 1859-1867.	1.3	39
88	Spatial and temporal intratumour heterogeneity has potential consequences for single biopsy-based neuroblastoma treatment decisions. <i>Nature Communications</i> , 2021, 12, 6804.	5.8	39
89	MicroRNAs in the pathogenesis of neuroblastoma. <i>Cancer Letters</i> , 2009, 274, 10-15.	3.2	37
90	Identification of a novel recurrent 1q42.2 $\hat{1}$ qter deletion in high risk <i>MYCN</i> single copy 11q deleted neuroblastomas. <i>International Journal of Cancer</i> , 2012, 130, 2599-2606.	2.3	37

#	ARTICLE	IF	CITATIONS
91	Focal DNA Copy Number Changes in Neuroblastoma Target MYCN Regulated Genes. PLoS ONE, 2013, 8, e52321.	1.1	37
92	Sensitivity to cdk1-inhibition is modulated by p53 status in preclinical models of embryonal tumors. Oncotarget, 2015, 6, 15425-15435.	0.8	37
93	Identification of Dynamic Proteome Changes Upon Ligand Activation of Trk-Receptors Using Two-dimensional Fluorescence Difference Gel Electrophoresis and Mass Spectrometry. Molecular and Cellular Proteomics, 2005, 4, 291-299.	2.5	36
94	Photodynamic Therapy in Retinoblastoma: Effects of Verteporfin on Retinoblastoma Cell Lines. , 2008, 49, 3158.		36
95	Extended induction chemotherapy does not improve the outcome for high-risk neuroblastoma patients: results of the randomized open-label GPOH trial NB2004-HR. Annals of Oncology, 2020, 31, 422-429.	0.6	36
96	Long-term follow-up of pediatric patients receiving total body irradiation before hematopoietic stem cell transplantation and post-transplant survival of >2 years. Pediatric Blood and Cancer, 2013, 60, 1792-1797.	0.8	35
97	CADM1 is a strong neuroblastoma candidate gene that maps within a 3.72 Mb critical region of loss on 11q23. BMC Cancer, 2008, 8, 173.	1.1	34
98	Neuroblastoma tumorigenesis is regulated through the Nm23-H1/h-Prune C-terminal interaction. Scientific Reports, 2013, 3, 1351.	1.6	34
99	The GSK461364 PLK1 inhibitor exhibits strong antitumoral activity in preclinical neuroblastoma models. Oncotarget, 2017, 8, 6730-6741.	0.8	34
100	Towards a cancer mission in Horizon Europe: recommendations. Molecular Oncology, 2020, 14, 1589-1615.	2.1	33
101	The First European Interdisciplinary Ewing Sarcoma Research Summit. Frontiers in Oncology, 2012, 2, 54.	1.3	32
102	Expression of neurotrophin receptor TrkA inhibits angiogenesis in neuroblastoma. Medical and Pediatric Oncology, 2000, 35, 569-572.	1.0	31
103	Relative Quantitative RT-PCR Protocol for <i>TrkB</i> Expression in Neuroblastoma Using <i>GAPD</i> as an Internal Control. BioTechniques, 2000, 28, 681-691.	0.8	31
104	The metallophosphodiesterase Mpped2 impairs tumorigenesis in neuroblastoma. Cell Cycle, 2012, 11, 569-581.	1.3	30
105	MYCN and HDAC5 transcriptionally repress <i>CD9</i> to trigger invasion and metastasis in neuroblastoma. Oncotarget, 2016, 7, 66344-66359.	0.8	30
106	Transcription factor AP2alpha (TFAP2a) regulates differentiation and proliferation of neuroblastoma cells. Cancer Letters, 2008, 271, 56-63.	3.2	29
107	Targeted Therapy for Neuroblastoma: ALK Inhibitors. Klinische Padiatrie, 2013, 225, 303-308.	0.2	29
108	Translating Expression Profiling into a Clinically Feasible Test to Predict Neuroblastoma Outcome. Clinical Cancer Research, 2007, 13, 1459-1465.	3.2	28

#	ARTICLE	IF	CITATIONS
109	Accelerating drug development for neuroblastoma - New Drug Development Strategy: an Innovative Therapies for Children with Cancer, European Network for Cancer Research in Children and Adolescents and International Society of Paediatric Oncology Europe Neuroblastoma project. <i>Expert Opinion on Drug Discovery</i> , 2017, 12, 1-11.	2.5	28
110	p75 mediated apoptosis in neuroblastoma cells is inhibited by expression of TrkA. <i>Medical and Pediatric Oncology</i> , 2000, 35, 573-576.	1.0	27
111	Phox2B mutations and the Delta-Notch pathway in neuroblastoma. <i>Cancer Letters</i> , 2005, 228, 59-63.	3.2	27
112	Bone morphogenetic protein-7 is a MYC target with prosurvival functions in childhood medulloblastoma. <i>Oncogene</i> , 2011, 30, 2823-2835.	2.6	27
113	Multiple Active Compounds from <i>Viscum album L.</i> Synergistically Converge to Promote Apoptosis in Ewing Sarcoma. <i>PLoS ONE</i> , 2016, 11, e0159749.	1.1	27
114	The KDM1A histone demethylase is a promising new target for the epigenetic therapy of medulloblastoma. <i>Acta Neuropathologica Communications</i> , 2013, 1, 19.	2.4	26
115	Next-generation RNA sequencing reveals differential expression of MYCN target genes and suggests the mTOR pathway as a promising therapy target in MYCN-amplified neuroblastoma. <i>International Journal of Cancer</i> , 2013, 132, E106-15.	2.3	26
116	Neuroblastoma in dialog with its stroma: NTRK1 is a regulator of cellular cross-talk with Schwann cells. <i>Oncotarget</i> , 2014, 5, 11180-11192.	0.8	26
117	Absence of telomerase reverse transcriptase promoter mutations in neuroblastoma. <i>Biomedical Reports</i> , 2015, 3, 443-446.	0.9	25
118	Regional hyperthermia combined with chemotherapy in paediatric, adolescent and young adult patients: current and future perspectives. <i>Radiation Oncology</i> , 2016, 11, 65.	1.2	25
119	A Reproducible Bioprinted 3D Tumor Model Serves as a Preselection Tool for CAR T Cell Therapy Optimization. <i>Frontiers in Immunology</i> , 2021, 12, 689697.	2.2	25
120	Exon-level expression analyses identify MYCN and NTRK1 as major determinants of alternative exon usage and robustly predict primary neuroblastoma outcome. <i>British Journal of Cancer</i> , 2012, 107, 1409-1417.	2.9	24
121	Class I histone deacetylases (HDAC) critically contribute to Ewing sarcoma pathogenesis. <i>Journal of Experimental and Clinical Cancer Research</i> , 2021, 40, 322.	3.5	24
122	Xenogeneic immunization with human tyrosine hydroxylase DNA vaccines suppresses growth of established neuroblastoma. <i>Molecular Cancer Therapeutics</i> , 2009, 8, 2392-2401.	1.9	23
123	Current Concepts for Diagnosis and Treatment of Retinoblastoma in Germany: Aiming for Safe Tumor Control and Vision Preservation. <i>Klinische Padiatrie</i> , 2012, 224, 339-347.	0.2	23
124	Chemoreduction improves eye retention in patients with retinoblastoma: a report from the German Retinoblastoma Reference Centre. <i>British Journal of Ophthalmology</i> , 2013, 97, 1277-1283.	2.1	23
125	Age-Dependent Presentation and Clinical Course of 1465 Patients Aged 0 to Less than 18 Years with Ovarian or Testicular Germ Cell Tumors; Data of the MAKEI 96 Protocol Revisited in the Light of Prenatal Germ Cell Biology. <i>Cancers</i> , 2020, 12, 611.	1.7	23
126	Expression of Apo-3 and Apo-3L in primitive neuroectodermal tumours of the central and peripheral nervous system. <i>European Journal of Cancer</i> , 2002, 38, 92-98.	1.3	22

#	ARTICLE	IF	CITATIONS
127	Identification of 2 putative critical segments of 17q gain in neuroblastoma through integrative genomics. <i>International Journal of Cancer</i> , 2008, 122, 1177-1182.	2.3	22
128	HLA-haploidentical hematopoietic stem cell transplantation in pediatric patients with hemoglobinopathies: current practice and new approaches. <i>Bone Marrow Transplantation</i> , 2019, 54, 743-748.	1.3	22
129	Synergistic activity of BET inhibitor MK-8628 and PLK inhibitor Volasertib in preclinical models of medulloblastoma. <i>Cancer Letters</i> , 2019, 445, 24-33.	3.2	22
130	German Cancer Consortium (DKTK) â€“ A national consortium for translational cancer research. <i>Molecular Oncology</i> , 2019, 13, 535-542.	2.1	22
131	Targeted Analysis of Cell-free Circulating Tumor DNA is Suitable for Early Relapse and Actionable Target Detection in Patients with Neuroblastoma. <i>Clinical Cancer Research</i> , 2022, 28, 1809-1820.	3.2	22
132	Impairment of Bone Health in Pediatric Patients with Hemolytic Anemia. <i>PLoS ONE</i> , 2014, 9, e108400.	1.1	21
133	Mutations in ALK signaling pathways conferring resistance to ALK inhibitor treatment lead to collateral vulnerabilities in neuroblastoma cells. <i>Molecular Cancer</i> , 2022, 21, .	7.9	21
134	High resolution tiling-path BAC array deletion mapping suggests commonly involved 3p21-p22 tumor suppressor genes in neuroblastoma and more frequent tumors. <i>International Journal of Cancer</i> , 2007, 120, 533-538.	2.3	20
135	Logic Learning Machine creates explicit and stable rules stratifying neuroblastoma patients. <i>BMC Bioinformatics</i> , 2013, 14, S12.	1.2	20
136	Expression of NTRK1/TrkA affects immunogenicity of neuroblastoma cells. <i>International Journal of Cancer</i> , 2013, 133, 908-919.	2.3	20
137	Small-Molecule Dual PLK1 and BRD4 Inhibitors are Active Against Preclinical Models of Pediatric Solid Tumors. <i>Translational Oncology</i> , 2020, 13, 221-232.	1.7	20
138	Tumor-Derived Extracellular Vesicles Impair CD171-Specific CD4+ CAR T Cell Efficacy. <i>Frontiers in Immunology</i> , 2020, 11, 531.	2.2	20
139	Prohibitin promotes dedifferentiation and is a potential therapeutic target in neuroblastoma. <i>JCI Insight</i> , 2019, 4, .	2.3	20
140	VEGF plasma levels in nonruptured intracranial aneurysms. <i>Neurosurgical Review</i> , 2006, 29, 26-29.	1.2	19
141	Targeting tachykinin receptors in neuroblastoma. <i>Oncotarget</i> , 2017, 8, 430-443.	0.8	19
142	Expression of the TrkA or TrkB receptor tyrosine kinase alters the double-strand break (DSB) repair capacity of SY5Y neuroblastoma cells. <i>DNA Repair</i> , 2008, 7, 1757-1764.	1.3	18
143	Production of Chick Embryo Extract for the Cultivation of Murine Neural Crest Stem Cells. <i>Journal of Visualized Experiments</i> , 2010, , .	0.2	18
144	Improving Stratification for Children With Late Bone Marrow B-Cell Acute Lymphoblastic Leukemia Relapses With Refined Response Classification and Integration of Genetics. <i>Journal of Clinical Oncology</i> , 2019, 37, 3493-3506.	0.8	18

#	ARTICLE	IF	CITATIONS
145	A Novel Standard for Systematic Reporting of Neuroblastoma Surgery. <i>Annals of Surgery</i> , 2020, Publish Ahead of Print, .	2.1	18
146	Different effects of TrkA expression in neuroblastoma cell lines with or without MYCN amplification. <i>Medical and Pediatric Oncology</i> , 2000, 35, 623-627.	1.0	17
147	Neurotrophin receptor expression in human primary retinoblastomas and retinoblastoma cell lines. <i>Pediatric Blood and Cancer</i> , 2008, 50, 218-222.	0.8	17
148	Neoadjuvant/adjuvant treatment of high-risk retinoblastoma: a report from the German Retinoblastoma Referral Centre. <i>British Journal of Ophthalmology</i> , 2015, 99, 949-953.	2.1	17
149	Targeting of MYCN by means of DNA vaccination is effective against neuroblastoma in mice. <i>Cancer Immunology, Immunotherapy</i> , 2015, 64, 1215-1227.	2.0	17
150	Viscum TT induces apoptosis and alters IAP expression in osteosarcoma in vitro and has synergistic action when combined with different chemotherapeutic drugs. <i>BMC Complementary and Alternative Medicine</i> , 2017, 17, 26.	3.7	17
151	CD28 Co-Stimulus Achieves Superior CAR T Cell Effector Function against Solid Tumors Than 4-1BB Co-Stimulus. <i>Cancers</i> , 2021, 13, 1050.	1.7	17
152	The low-affinity neurotrophin receptor, p75, is upregulated in ganglioneuroblastoma/ganglioneuroma and reduces tumorigenicity of neuroblastoma cells <i>in vivo</i> . <i>International Journal of Cancer</i> , 2009, 124, 2488-2494.	2.3	15
153	CASP8 SNP D302H (rs1045485) Is Associated with Worse Survival in MYCN-Amplified Neuroblastoma Patients. <i>PLoS ONE</i> , 2014, 9, e114696.	1.1	15
154	Fast, In Vivo Model for Drug-Response Prediction in Patients with B-Cell Precursor Acute Lymphoblastic Leukemia. <i>Cancers</i> , 2020, 12, 1883.	1.7	15
155	The Quassinoid Derivative NBT-272 Targets Both the AKT and ERK Signaling Pathways in Embryonal Tumors. <i>Molecular Cancer Therapeutics</i> , 2010, 9, 3145-3157.	1.9	14
156	Proteomics: Techniques and Applications in Cancer Research. <i>Klinische Padiatrie</i> , 2003, 215, 293-297.	0.2	13
157	Application of microarray-based technology to neuroblastoma. <i>Cancer Letters</i> , 2005, 228, 13-20.	3.2	13
158	Inhibiting phosphoglycerate dehydrogenase counteracts chemotherapeutic efficacy against MYCN-amplified neuroblastoma. <i>International Journal of Cancer</i> , 2021, 148, 1219-1232.	2.3	13
159	Microarray-Analysis: A New Approach to Study the Molecular Mechanisms of Thermo-Chemotherapy. <i>Klinische Padiatrie</i> , 2003, 215, 298-302.	0.2	12
160	The mentoring of women for medical career development. <i>International Journal of Mentoring and Coaching in Education</i> , 2012, 1, 155-168.	0.7	12
161	Only strongly enhanced residual FDG uptake in early response PET (Deauville 5 or qPET ≥ 2) is prognostic in pediatric Hodgkin lymphoma: Results of the GPOH-HD2002 trial. <i>Pediatric Blood and Cancer</i> , 2019, 66, e27539.	0.8	12
162	TrkA signal transduction pathways in neuroblastoma. <i>Medical and Pediatric Oncology</i> , 2001, 36, 108-110.	1.0	11

#	ARTICLE	IF	CITATIONS
163	Transcriptomic and proteomic insight into the effects of a defined European mistletoe extract in Ewing sarcoma cells reveals cellular stress responses. <i>BMC Complementary and Alternative Medicine</i> , 2017, 17, 237.	3.7	11
164	Multiplexed Quantification of Four Neuroblastoma DNA Targets in a Single Droplet Digital PCR Reaction. <i>Journal of Molecular Diagnostics</i> , 2020, 22, 1309-1323.	1.2	11
165	GD2-directed bispecific trifunctional antibody outperforms dinutuximab beta in a murine model for aggressive metastasized neuroblastoma. , 2021, 9, e002923.		11
166	Yoga, Meditation and Mindfulness in pediatric oncology – A review of literature. <i>Complementary Therapies in Medicine</i> , 2021, 63, 102791.	1.3	11
167	Reanalysis of neuroblastoma expression profiling data using improved methodology and extended follow-up increases validity of outcome prediction. <i>Cancer Letters</i> , 2009, 282, 55-62.	3.2	10
168	A European paediatric cancer mission: aspiration or reality?. <i>Lancet Oncology</i> , The, 2019, 20, 1200-1202.	5.1	10
169	Synovial sarcoma disease characteristics and primary tumor sites differ between patient age groups: a report of the Cooperative Weichteilsarkom Studiengruppe (CWS). <i>Journal of Cancer Research and Clinical Oncology</i> , 2020, 146, 953-960.	1.2	10
170	Reflection of neuroblastoma intratumor heterogeneity in the new OHC&NB1 disease model. <i>International Journal of Cancer</i> , 2020, 146, 1031-1041.	2.3	9
171	Adjuvant therapy of histopathological risk factors of retinoblastoma in Europe: A survey by the European Retinoblastoma Group (EURbG). <i>Pediatric Blood and Cancer</i> , 2021, 68, e28963.	0.8	9
172	The BCL2-938 C&#gt;A promoter polymorphism is associated with risk group classification in children with acute lymphoblastic leukemia. <i>BMC Cancer</i> , 2013, 13, 452.	1.1	8
173	Immunotherapy with the trifunctional anti-CD20&#A—anti-CD3 antibody FBTA05 in a patient with relapsed t(8;14)-positive post-transplant lymphoproliferative disease. <i>Leukemia and Lymphoma</i> , 2017, 58, 1989-1992.	0.6	8
174	Pharmaceutically inhibiting polo&#like kinase 1 exerts a broad anti&#tumour activity in retinoblastoma cell lines. <i>Clinical and Experimental Ophthalmology</i> , 2017, 45, 288-296.	1.3	8
175	Central memory phenotype drives success of checkpoint inhibition in combination with CAR T cells. <i>Molecular Carcinogenesis</i> , 2020, 59, 724-735.	1.3	8
176	Proton Beam Therapy for Children With Neuroblastoma: Experiences From the Prospective KiProReg Registry. <i>Frontiers in Oncology</i> , 2020, 10, 617506.	1.3	8
177	Inhibiting PHGDH with NCT-503 reroutes glucose-derived carbons into the TCA cycle, independently of its on-target effect. <i>Journal of Enzyme Inhibition and Medicinal Chemistry</i> , 2021, 36, 1282-1289.	2.5	8
178	Discovery of Spatial Peptide Signatures for Neuroblastoma Risk Assessment by MALDI Mass Spectrometry Imaging. <i>Cancers</i> , 2021, 13, 3184.	1.7	8
179	The mitochondrial genetic landscape in neuroblastoma from tumor initiation to relapse. <i>Oncotarget</i> , 2016, 7, 6620-6625.	0.8	8
180	Synergistic Antitumour Properties of <i>viscum</i> in Alveolar Rhabdomyosarcoma. <i>Journal of Immunology Research</i> , 2017, 2017, 1-13.	0.9	7

#	ARTICLE	IF	CITATIONS
181	More than just warmth – The perception of warmth and relaxation through warming compresses. <i>Complementary Therapies in Medicine</i> , 2020, 54, 102537.	1.3	7
182	Evaluation of an Integrative Care Program in Pediatric Oncology. <i>Integrative Cancer Therapies</i> , 2020, 19, 153473542092839.	0.8	7
183	Development of an Integrative Care Program in a Pediatric Oncology Unit. <i>Complementary Medicine Research</i> , 2021, 28, 131-138.	0.5	7
184	Eye Tumors in Childhood as First Sign of Tumor Predisposition Syndromes: Insights from an Observational Study Conducted in Germany and Austria. <i>Cancers</i> , 2021, 13, 1876.	1.7	7
185	A small kiss of death for cancer. <i>Nature Medicine</i> , 2010, 16, 1079-1081.	15.2	6
186	Minichromosome Maintenance Complex Is a Critical Node in the miR-183 Signaling Network of MYCN-Amplified Neuroblastoma Cells. <i>Journal of Proteome Research</i> , 2016, 15, 2178-2186.	1.8	6
187	Integrative care for children with cancer. Project design for the development of an integrative care programme for use in paediatric oncology. <i>Complementary Therapies in Medicine</i> , 2018, 41, 247-251.	1.3	6
188	Long-term follow-up of children with neuroblastoma receiving radiotherapy to metastatic lesions within the German Neuroblastoma Trials NB97 and NB2004. <i>Strahlentherapie Und Onkologie</i> , 2021, 197, 683-689.	1.0	6
189	Perception of integrative care in paediatric oncology – perspectives of parents and patients. <i>Complementary Therapies in Medicine</i> , 2021, 56, 102624.	1.3	6
190	External application of liver compresses to reduce fatigue in patients with metastatic cancer undergoing radiation therapy, a randomized clinical trial. <i>Radiation Oncology</i> , 2021, 16, 76.	1.2	6
191	ALK Inhibitors in Neuroblastoma: A Sprint from Bench to Bedside. <i>Clinical Cancer Research</i> , 2021, 27, 3507-3509.	3.2	6
192	Circulating Cell-Free DNA Assessment in Biofluids from Children with Neuroblastoma Demonstrates Feasibility and Potential for Minimally Invasive Molecular Diagnostics. <i>Cancers</i> , 2022, 14, 2080.	1.7	6
193	Lack of association between MDM2 promoter SNP309 and clinical outcome in patients with neuroblastoma. <i>Pediatric Blood and Cancer</i> , 2014, 61, 1867-1870.	0.8	5
194	Towards a Cancer Mission in Horizon Europe. <i>Molecular Oncology</i> , 2019, 13, 2301-2304.	2.1	5
195	ADCC can improve graft vs leukemia effect after T- and B-cell depleted haploidentical stem cell transplantation in pediatric B-lineage ALL. <i>Bone Marrow Transplantation</i> , 2019, 54, 689-693.	1.3	5
196	Allogeneic hematopoietic stem cell transplantation from sibling and unrelated donors in pediatric patients with sickle cell disease – A single center experience. <i>Pediatric Transplantation</i> , 2021, 25, e13892.	0.5	5
197	Identification and Tumour-Binding Properties of a Peptide with High Affinity to the Disialoganglioside GD2. <i>PLoS ONE</i> , 2016, 11, e0163648.	1.1	5
198	Neuroblastoma signalling models unveil combination therapies targeting feedback-mediated resistance. <i>PLoS Computational Biology</i> , 2021, 17, e1009515.	1.5	5

#	ARTICLE	IF	CITATIONS
199	Whole-genome paired-end analysis confirms remarkable genomic stability of atypical teratoid/rhabdoid tumors. <i>Genes Chromosomes and Cancer</i> , 2013, 52, 983-985.	1.5	4
200	Feasibility of VECOPA, a dose-intensive chemotherapy regimen for children and adolescents with intermediate and advanced stage Hodgkin lymphoma: results of the GPOH-HD-2002/VECOPA pilot trial. <i>Leukemia and Lymphoma</i> , 2015, 56, 1308-1314.	0.6	4
201	Donor selection in a pediatric stem cell transplantation cohort using PIRCHE and HLA-DPB1 typing. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28127.	0.8	4
202	A G316A Polymorphism in the Ornithine Decarboxylase Gene Promoter Modulates MYCN-Driven Childhood Neuroblastoma. <i>Cancers</i> , 2021, 13, 1807.	1.7	4
203	RITA displays anti-tumor activity in medulloblastomas independent of TP53 status. <i>Oncotarget</i> , 2017, 8, 27882-27891.	0.8	4
204	Genomic Evolution and Personalized Therapy of an Infantile Fibrosarcoma Harboring an NTRK Oncogenic Fusion. <i>JCO Precision Oncology</i> , 2022, , .	1.5	4
205	Discovery of a New Bioactive Molecule for Neuroblastoma. <i>Chemical Biology and Drug Design</i> , 2013, 82, 233-241.	1.5	3
206	Comparing efficacy and side effects of two systemic chemotherapy regimens for eye-preserving therapy in children with retinoblastoma. <i>Pediatric Blood and Cancer</i> , 2022, 69, e29362.	0.8	3
207	Individualized risk assessment in neuroblastoma: does the tumoral metabolic activity on 123I-MIBG SPECT predict the outcome?. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 2203-2212.	3.3	2
208	Transmission of chromosomally integrated human herpes virus-6A via haploidentical stem cell transplantation poses a risk for virus reactivation and associated complications. <i>Bone Marrow Transplantation</i> , 2020, 55, 260-264.	1.3	2
209	Clinical Presentation and Management of a Dinutuximab Beta Extravasation in a Patient with Neuroblastoma. <i>Children</i> , 2021, 8, 91.	0.6	2
210	Efficacy of Brincidofovir in Pediatric Stem Cell Transplant Recipients With Adenovirus Infections. <i>Journal of the Pediatric Infectious Diseases Society</i> , 2021, , .	0.6	2
211	Germline Mutations Including the Rare Pathogenic Variant c.3206delC in the ATM Gene Cause Ataxia Teleangiectasia-Associated Primary Central Nervous System Lymphoma. <i>Children</i> , 2021, 8, 469.	0.6	2
212	Neuroblastoma Risk Assessment and Treatment Stratification with Hybrid Capture-Based Panel Sequencing. <i>Journal of Personalized Medicine</i> , 2021, 11, 691.	1.1	2
213	p75 mediated apoptosis in neuroblastoma cells is inhibited by expression of TrkA. , 2000, 35, 573.		2
214	Stem Cell Transplantation in Advanced Stage Sickle Cell Disease with Haploidentical T-Cell Depleted PBSC Yields Comparable Outcomes to Matched Sibling Donor Bone Marrow: Results of a Pilot Study. <i>Blood</i> , 2018, 132, 3455-3455.	0.6	2
215	Inhibiting Lysine Demethylase 1A Improves L1CAM-Specific CAR T Cell Therapy by Unleashing Antigen-Independent Killing via the FAS-FASL Axis. <i>Cancers</i> , 2021, 13, 5489.	1.7	2
216	A novel human processed gene, DAD-R, maps to 12p12 and is expressed in several organs. <i>FEBS Letters</i> , 2000, 473, 233-236.	1.3	1

#	ARTICLE	IF	CITATIONS
217	Angiogenic Cytokines: Quantitative and Functional Analysis. , 2003, 215, 117-134.		1
218	Insight into mistletoe's mechanism of action of targeting pediatric Ewing Sarcoma. Phytomedicine, 2015, 22, S25.	2.3	1
219	The INFORM personalized medicine study for high-risk pediatric cancer patients.. Journal of Clinical Oncology, 2017, 35, 10509-10509.	0.8	1
220	Assessment of Calcineurin Inhibitor-Associated Neurotoxicity in Patients with Sickle Cell Disease Receiving a Matched Sibling Donor or T-Cell Depleted Haploidentical Hematopoietic Stem Cell Transplantation. Blood, 2018, 132, 2088-2088.	0.6	1
221	Apoptosis Induction by TRAIL. , 2003, 215, 95-116.		0
222	MYCN transcriptionally represses CD9 to trigger an invasion-metastasis cascade in neuroblastoma. Molecular and Cellular Pediatrics, 2015, 2, A13.	1.0	0
223	Sinusoidal Obstruction Syndrome Following Myeloablative Therapy and Tranexamic Acid Treatment for Hemorrhage in Two Patients with Neuroblastoma. Children, 2020, 7, 198.	0.6	0
224	Neuroblastom. Springer Reference Medizin, 2021, , 1-14.	0.0	0
225	Hemostatic Management in an Infant With Neuroblastoma and Severe Hemophilia B With Extended Half-life Recombinant Factor IX Fusion Protein. Journal of Pediatric Hematology/Oncology, 2021, Publish Ahead of Print, .	0.3	0
226	Identification of New Markers for the Detection of Minimal Residual Disease in AML by Gene Expression Profiling and Real Time PCR.. Blood, 2004, 104, 2008-2008.	0.6	0
227	Identification of a Set of Seven Genes for the Monitoring of Minimal Residual Disease in Pediatric Acute Myeloid Leukemia.. Blood, 2005, 106, 1461-1461.	0.6	0
228	Neuroblastom. , 2009, , 771-778.		0
229	Abstract 1683: ALK F1174L kinase activity as driver of cell proliferation in neuroblastoma cell line models and neuroblastoma tumors. , 2012, , .		0
230	Abstract 4596: LIN28B drives neuroblastoma oncogenesis through let7-MYCN signaling.. , 2013, , .		0
231	Long-Term Structured Follow-up Is Essential After Curative Cancer Treatment. Deutsches Ärztblatt International, 2014, 111, 1-2.	0.6	0
232	Response to Front-Line Imatinib Treatment in Children and Adolescents with CML - Data from a Large Pediatric Cohort. Blood, 2017, 130, 898-898.	0.6	0
233	Quantification of Cardiovascular Regulation Applying Heart Rate Variability Analyses for Different Warm and Moist Chest Compresses in Healthy Subjects. , 2022, 28, 268-277.		0
234	Personalisierte Medizin in der Kinderonkologie: Wo stehen wir heute?. PÄdiatrie Up2date, 2021, 16, 325-342.	0.0	0

#	ARTICLE	IF	CITATIONS
235	Pre-operative radiotherapy is associated with superior local relapse-free survival in advanced synovial sarcoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 0, , .	1.2	0